Likewise, we found increased levels of γH2AX, a marker of DNA damage, in the cytoplasmic and nuclear fractions of breast cancer cells treated with a DOT1L inhibitor (Fig. 5A, Supplementary Fig. S10A, B). This evidence concerns the gene DOT1L and breast carcinoma.